Intravenous busulfan as preparative regimen in pediatric patients receiving hematopoietic stem cell transplantation: The preliminary experience in Taiwan

Journal of the Chinese Medical Association

Volumn 67, Issue 3, 2004, Pages 117-122

  Lee, Ming Yang ^a,b   Chiou, Tzeon Jye ^a,b   Bai, Li Yuan ^a,b   Hsiao, Liang Tsai ^a,b   Hung, Giun Yi ^a,b   Chang, Chia Yau ^a,b   Chen, Po Min ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Acute graft versus host disease; Busulfan; Hematopoietic stem cell transplantation; Hepatic veno occlusive disease

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; METHOTREXATE; PHENYTOIN;

ACUTE GRAFT REJECTION; ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; ASIA; CASE REPORT; CHILD; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; LIVER VEIN OBSTRUCTION; MALE; MUCOSA INFLAMMATION; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; TAIWAN;

ADOLESCENT; BUSULFAN; CHILD; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INJECTIONS, INTRAVENOUS; MALE; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 2542478050     PISSN: 17264901     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Thomas ED. Stem cell transplantation: past, present and future. Stem Cells 1994;12:539-44.
2. Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB, et al. Marrow transplantation for acute non-lymphocytic leukemia after treatment with busulfan and cycloposphamide. N Engl J Med 1983;309:1347-53.
3. Bushhouse S, Ramsay NK, Pescovitz OH, Kim T, Robison LL. Growth in children following irradiation for bone marrow transplantation. Am J Pediatr Hematol Oncol 1989;11:114-40.
4. Sanders JE. Bone marrow transplantation for pediatric leukemia. Pediatr Ann 1991;20:671-6.
5. Liesner RJ, Leiper AD, Hann IM, Chessells JM. Late effects of intensive treatment for acute myeloid leukemia and myelodysplasia in childhood. J Clin Oncol 1994;12:916-24.
6. Cohen A, van-Lint MT, Uderzo C, Rovelli A, Lavagetto A, Vitale V, et al. Growth in patients after allogeneic bone marrow transplant for hematological disease in childhood. Bone Marrow Transplant 1995;15:343-8.
7. Bhatia S, Ramsay NK, Steinbuch M, Dusenbery KE, Shapiro RS, Weisdorf DJ, et al. Malignant neoplasms following bone marrow transplantation. Blood 1996;87:3633-9.
8. Socie G, Curtis RE, Deeg HJ, Soboeinski KA, Filiporich AH, Travis LB, et al. New malignant disease after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol 2000;18:348-57.
9. Socie G, Clift RA, Blaise D, Devergie A, Ringden O, Martin PJ, et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: a long-term follow-up of 4 randomized studies. Blood 2001;98:3569-74.
10. Vassal G, Gouyette A, Hartmann O, Pico JL, Lemerle J, et al. Pharmacokinetics of high-dose busulfan in children. Cancer Chemother Pharmacol 1989;24:386-90.
11. Grochow LB, Krivit W, Whitley CB, Blazar B. Busulfan disposition in children. Blood 1990;75:1723-7.
12. Grochow LB, Jones RJ, Brundrett RB, Brame HG, Chen TL, Saral R, et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989;25:55-61.
13. Slattery JT, Sanders JE, Buckner CD, Schaffer RL, Lambert KW, Langer FP, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995;16:31-42.
14. Dix SP, Wingard JR, Mullins RE, Jerkanica I, Davidson TG, Gilmore CE, et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996;17:225-30.
15. Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997;89:3055-60.
16. Bolinger AM, Zangwill AB, Slattery JT, Glidden D, DeSantes K, Heyn L, et al. An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease. Bone Marrow Transplant 2000;25:925-30.
17. Copelan EA, Bechtel TP, Avalos BR, Elder PJ, Ezzon SA, Scholl MD, et al. Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation. Bone Marrow Transplant 2001;27:1121-4.
18. Vassal G, Deroussent A, Hartmann O, Challine D, Benhamou E, Valteau-Couanet D, et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res 1990;50:6203-7.
19. Ljungman P, Hassan M, Bekassy AN, Ringden O, Oberg G. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1997;20:909-13.
20. Peters WP, Henner WD, Grochow LB, Olsen G, Edwards S, Stanbuck H, et al. Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors. Cancer Res 1987;47: 6402-6.
21. Bhagwatwar HP, Phadungpoja S, Chow DS, Andersson BS. Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy. Cancer Chemother Pharmacol 1996;37:401-8.
22. Wall DA, Chan KW, Nieder M, Hayaski R, Feingold J, Klemperer M, et al. Phase II trial of intravenous busulfan (busulfex®) with cyclophosphamide in pediatric allogencic hematopoietic cell transplantation (HCT): pharmacokinetics, toxicity and efficacy (a Pediatric Blood & Marrow Transplant Consurtium study). Blood 2000; 96:480.
23. Tran H, Madden T, Petropoulos D, Worth LL, Felix EA, Sprigg-Saenz HA, et al. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies. Bone Marrow Transplant 2000;26:463-70.
24. Andersson BS, Madden T, Tran HT, Hu WW, Blume KG, Chow DS, et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy; a phase I study. Bio Blood Marrow Transplant 2000;16:548-54.
25. Andersson BS, Kashyap A, Gian V, Wingard JR, Fernandez H, Cagnoni PJ, et al. Conditioning therapy with intravenous Busulfan and Cyclophosphamide (IV BuCy2) for Hematologic Malignancies prior to allogencic stem cell transplantation: a phase II study. Bio Blood Marrow Transplant 2002;8:145-54.
26. Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochow LB, Braine HG, et al. Veno-occlusive disease of the liver following bone marrow transplantation. Transplantation 1987;44: 778-83.
27. Cremers S, Schoemaker R, Bredius R, den Hartigh J, Ball L, Twiss I, et al. Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation. Br J Clin Pharmacol 2002;53:386-9.
28. McCune JS, Gibbs JP, Slattery JT. Plasma concentration monitoring of busulfan: Does it improve clinical outcome? Clin Pharmacol 2000;39:155-65.
29. Tran HT, Madden T, Worth LL, Mullin CA, McMullin BA, Choroszy MS, et al. Pharmacokinetic (PK) Guided Dose Adjustment of Intravenous Busulfan (IVBU) (Busulfext™) in Pediatric Patients Receiving Busulfan-Based Preparative Regimen for Stem Cell Transplantation (SCT). Blood 2001;98:198.
30. Ksshyap A, Wingard J, Cagnoni P, Roy J, Tarantolo S, Hu W, et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant 2002;8:493-500.